Health & Science

UC Berkeley’s Groundbreaking Study Exploring Psilocybin’s Effects on Perception

Jun 14 • 6 min read

The UC Berkeley Center for the Science of Psychedelics has embarked on an unprecedented study to explore why psilocybin, a psychoactive compound found in certain mushrooms, alters visual perception in humans. This investigation represents the university’s first human trials involving a Schedule I substance, classified by the federal government as having no accepted medical use….

Lykos Therapeutics Addresses Concerns Over MDMA Treatment for PTSD

Jun 14 • 5 min read

A week after an FDA committee voted against recommending midomafetamine (MDMA) treatment for post-traumatic stress disorder (PTSD), Lykos Therapeutics is working to clarify the situation and address concerns that have emerged in the broader conversation. This effort comes in the wake of significant public discourse surrounding the potential benefits and risks associated with the psychoactive…

Effective Psychedelic Treatment for Long-COVID Symptoms: A Case Study

Jun 7 • 4 min read

Long-COVID, also known as post-acute sequelae of SARS-CoV-2 infection, encompasses a range of symptoms that persist even after an individual has seemingly recovered from COVID-19. These symptoms can include cognitive impairment, fatigue, depression, anxiety, headaches, and joint pain. Currently, effective treatments for long-COVID are limited. However, a recent case study has highlighted the potential of…

FSD Pharma Triumphs in Legal Dispute Against Former CEO Dr. Raza Bokhari

May 31 • 3 min read

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) has emerged victorious in its prolonged legal battle with the company’s former CEO, Dr. Raza Bokhari. Following years of litigation and an intensive eight-day evidentiary hearing, an arbitrator ruled against Bokhari, granting FSD Pharma three awards, including damages and compensation for the company’s arbitration-related fees and costs. On…

FTC’s Final Rule Amendment to the Health Breach Notification Rule and Its Implications

May 31 • 5 min read

On April 26, 2024, the Federal Trade Commission (FTC) issued a significant final rule amending its Health Breach Notification Rule (HBN Rule). This amendment aims to address the evolving landscape of personal health records (PHRs) and related technologies that fall outside the regulatory scope of the Health Insurance Portability and Accountability Act of 1996 (HIPAA)….

Pages: 1234567891011121314